A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome

Status:
Withdrawn

Trial end date:
2018-09-12

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Cemdisiran in patients with aHUS.

Phase 2

Alnylam Pharmaceuticals